Martin Whitaker, Chief Executive Officer, sold 44,810 Ordinary Shares at a price of 37 pence per Ordinary Share and his ISA purchased 44,810 Ordinary Shares at a price of 37.1 pence per Ordinary Share.. Additionally, Martin Whitaker purchased a total of 15,104 Ordinary Shares at 38 pence per share, to be held in pension schemes for the beneficial interest of his...
RNS Number: 9212 H Diurnal Group PLC 05 August 2019 5 August 2019. Grant of Deferred Share Awards. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the following deferred bonus share awards over ordinary shares of 5 pence in Diurnal were granted under the Diurnal Group plc Long Term...
RNS Number: 9265 G Diurnal Group PLC 26 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8272 E Diurnal Group PLC 08 July 2019 8 July 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the issue and allotment of 11,884 ordinary shares of £0.05 to John Goddard, Non-Executive Director of the Company, as part of a pre-existing arrangement whereby he receives...
Diurnal Group Plc (DNL.L) Announced that an application for market authorisation for Alkindi (hydrocortisone granules in capsules for opening) has been submitted to the Australian Therapeutic Good Administration (TGA) for the indication "replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents. Recently, Alkindi was granted Orphan Drug Designation in Australia, a valuable regulatory privilege that provides significant benefits, including waiver of application, evaluation and annual registration fees. Alkindi is already approved and marketed in Europe and is the first preparation of hydrocortisone, which is specifically designed for use in children suffering from AI, including the related condition CAH.
Alkindi ® Market Authorisation Application Submitted in Australia. Significant opportunity to address unmet medical need in paediatric adrenal insufficiency in Australia. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that an application for market authorisation for...
Alkindi ® Market Authorisation Application Submitted in Australia. Significant opportunity to address unmet medical need in paediatric adrenal insufficiency in Australia. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that an application for market authorisation for...
Alkindi ® Market Authorisation Application Submitted in Australia. Significant opportunity to address unmet medical need in paediatric adrenal insufficiency in Australia. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that an application for market authorisation for...
RNS Number: 5472 D Diurnal Group PLC 26 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Richard Bungay, Chief Financial Officer, purchased 8,000 Ordinary Shares at a price of 29.75 pence per Ordinary Share. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal...
RNS Number: 0864 D Diurnal Group PLC 21 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0862 D Diurnal Group PLC 21 June 2019 Correction: The following amendment has been made to the' Holding in Company' announcement released on 18 June 2019 at 17:30 under RNS No 6729 C.. The changes relate to sections 7, 8 and 9 in the Holding in Company announcement. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider...
RNS Number: 0316 D Diurnal Group PLC 21 June 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. RNS is approved by the Financial Conduct Authority to act...
RNS Number: 8070 C Diurnal Group PLC 19 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6729 C Diurnal Group PLC 18 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Martin Whitaker, Chief Executive Officer, subscribed for 19,230 ordinary shares of 5 pence each in Diurnal Group plc at a price of 26 pence per Ordinary Share. Richard Bungay, Chief Financial Officer, subscribed for 19,230 Ordinary Shares at a price of 26 pence per Ordinary Share. Peter Allen, Chairman, subscribed for 84,722 Ordinary Shares at a price of 26 pence...
Richard Ross, Chief Scientific Officer and his wife, Sarah Ross, sold in aggregate 148,300 Ordinary Shares at a price of 27 pence per Ordinary Share and their respective ISAs purchased 148,300 Ordinary Shares in aggregate at a price of 27.02 pence per Ordinary Share. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality...
RNS Number: 3518 C Diurnal Group PLC 14 June 2019 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...
Diurnal Group Plc (DNL.L) Announced that it has received valid acceptances and excess applications from Qualifying Shareholders in respect of a total of 2,229,578 Open Offer Shares pursuant to the terms of the Open Offer. This represents approximately 57.8% of the 3,857,617 Open Offer Shares. The Open Offer closed for acceptances on 13 June 2019. As a consequence and conditional on, amongst other things, Shareholder approval of the Resolutions at the General Meeting to be held later today and Admission, the company has raised gross proceeds of approximately £579,690 through the Open Offer and approximately £5.93 million (before expenses) in aggregate through the Placing and Open Offer
Diurnal Group plc
DNL.L
Diurnal Group plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    61.71M

Classification

Market Indices-

Locations

HQ
1 Callaghan Square
Cardiff
CF10 5BT
Watchlist